Remus Pharmaceuticals Limited
Promoters Mr. Arpit Deepakkumar Shah · Mr. Swapnil Jatinbhai Shah · Ms. Roma vinodbhai shah · Mrs. Anar Swapnil Shah
Against an issue price of ₹1,229. Split- and bonus-adjusted official closes — a past move, never a forecast.
Remus Pharmaceuticals Limited raised ₹50 crore through a SME-platform initial public offer.
The filing places it in Pharmaceuticals & Biotechnology and names four promoters: Mr. Arpit Deepakkumar Shah, Mr. Swapnil Jatinbhai Shah, Ms. Roma vinodbhai shah and Mrs. Anar Swapnil Shah.
The book was open from 17 May 2023 to 19 May 2023.
The issue was priced at ₹1,229 a share, from a band of ₹1,150 to ₹1,229.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
The shares listed on 29 May 2023.
The last official close on file is ₹903 (30 September 2026), which is 26.5% below the issue price.
It now trades as REMUS, and its filed financials are on its company page.
Shares sold in the issue at ₹1,229 last closed at ₹903.2.
See REMUS’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- How it was priced
- Book-built — the price was discovered inside a band from the bids received
- Listing sought at
- NSE
- Registered office
- Western India
- Company website
- www.remuspharma.com
- Registrar
- Link Intime India Private Limited
- Lead manager
- Other LM / BRLM
- Bidding opens17 May 2023
- Bidding closes19 May 2023
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing29 May 2023
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment29 Nov 2023already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment29 Nov 2024already free
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Weighted-average return on net worth over the same years: 21.70%.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Chandra Bhagat Pharma Limitednot in our universe | 99.1 | — | 3.0% | 1.06 | ₹9,408 cr |
| Trident Lifeline Limitednot in our universe | 21.5 | — | 82.7% | 6.92 | ₹2,177 cr |
| Vaishali Pharma Limited | 42.7 | — | 15.3% | 3.82 | ₹7,154 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Link Intime India Private Limited 2021 – 2026 | 175 14 measurable | +10.2% | 3 of 13 | 1 of 9 | 0 of 5 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive26 May 2023
- Red herring prospectus (RHP)· PDF · exchange archive12 May 2023
- Draft red herring prospectus (DRHP)· PDF · exchange archive10 Mar 2023
- In-principle approval (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.